25 October 2016 - Resubmission does better than initial submission.

The CADTH Canadian Drug Expert Committee has recommended that apremilast be reimbursed for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, if the following clinical criteria and conditions are met:

Clinical Criteria

 Patients with documented inadequate response, contraindication, or intolerance to conventional systemic therapies, such as methotrexate and cyclosporine.

 Patients otherwise eligible to receive but who have a contraindication (specifically: severe or repeated infections attributable to biologics, chronic hepatitis B infection, or active malignancy) that would preclude treatment with a biologic.

 Treatment discontinued if a Psoriasis Area and Severity Index (PASI) 75 response has not been demonstrated after 16 weeks of treatment with apremilast.

Conditions

 Patients should be managed in consultation with a dermatologist

 Reduced price.

Read CADTH outcome for apremilast